The UOKiK has granted conditional consent to ZakÅ‚ady Farmaceutyczne Polpharma’s takeover of ZakÅ‚ady Farmaceutyczne Polfa in Warszawa. Polpharma is owned by Genefar, and Polfa Warszawa is the state budget company belonging to Polski Holding Farmaceutyczny. Both companies are involved with the production and sale of pharmaceutical products.
The UOKiK found that the merger would lead to decreased competition in the markets for three antithrombotic drugs, as well as possible price increases. The terms of the consent thus require Polpharma to sell all its rights to three drugs within 18 months of the decision date. The drugs are: Polocard or Acard (antithrombotic drugs), Cipronex or Proxacin (fluorochinolones) and Sulfacetamidum natrium or Sulfacetamidum WZF 10% HEC.
Full content: UOKiK Press Release
Related content: The AZ Judgment: A Green Light for Further Action on Pharma and IP (Sean-Paul Brankin, Crowell & Moring)
Featured News
Hess Shareholders Approve $53 Billion Merger with Chevron
May 28, 2024 by
CPI
EU Regulators Engage with Telegram as App Nears Critical Usage Threshold
May 28, 2024 by
CPI
EEX Offers Remedies to Address EU Antitrust Concerns Over Nasdaq Deal
May 28, 2024 by
CPI
BRG Expands European Competition Practice with New Expert Team in Brussels
May 28, 2024 by
CPI
UK Law Empowers Regulators to Fine Big Tech Without Court Approval
May 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI